OrbiMed files Amendment to 13G, reports 0 RAPT shares (NASDAQ: RAPT)

Rhea-AI Filing Summary

OrbiMed Advisors LLC filed Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 0 shares of RAPT Therapeutics, Inc. common stock. The filing lists the class as Common Stock, par value $0.0001 per share (CUSIP 75382E109) and states 0.0% ownership. The filing notes that investment and voting power are exercised through a management committee of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership. The filing is signed by Carl L. Gordon on 05/15/2026.

Insights

Institutional Ownership Analyst

Amendment confirms no beneficial stake by OrbiMed in RAPT common stock.

The Schedule 13G/A amendment records an aggregate beneficial ownership of 0 shares and 0.0% of the class. It lists the security as Common Stock, par value $0.0001 (CUSIP 75382E109). The filing is signed by a managing committee member on 05/15/2026.

Because the reported position is zero, there is no immediate investor overhang or ownership signal from OrbiMed. Subsequent filings would be required to show any change in holdings.

Key Figures

Beneficially owned shares: 0 shares Percent of class: 0.0% Par value: $0.0001 per share +2 more

5 metrics

Beneficially owned shares 0 shares Amount beneficially owned reported in Schedule 13G/A

Percent of class 0.0% Percent of common stock class reported

Par value $0.0001 per share Common Stock par value as stated

CUSIP 75382E109 Identifier for RAPT common stock

Signature date 05/15/2026 Date signature was provided on the amendment

Key Terms

Schedule 13G/A, beneficially owned, disclaims beneficial ownership

3 terms

Schedule 13G/A regulatory

"Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned regulatory

"Amount beneficially owned: 0"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

disclaims beneficial ownership regulatory

"each of whom disclaims beneficial ownership of the shares"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:37 PM Learn about SEC filing dates

FAQ

What does OrbiMed's Schedule 13G/A amendment say about RAPT (RAPT)?

The amendment reports 0 shares beneficially owned and 0.0% of RAPT common stock (CUSIP 75382E109). It states OrbiMed exercises voting power through a management committee; committee members disclaim beneficial ownership.

Who exercises voting and investment power for OrbiMed in this filing?

OrbiMed states investment and voting power are exercised through a management committee of Carl L. Gordon, Sven H. Borho, and W. Carter Neild. Each committee member disclaims beneficial ownership of the reported shares.

Does the amendment indicate OrbiMed holds any economic interest in RAPT shares?

The amendment reports an aggregate beneficial ownership of 0 shares and 0.0% of the class, indicating no economic interest is reported by OrbiMed in RAPT common stock at the time of the filing.

When was the Schedule 13G/A amendment signed for OrbiMed's filing?

The amendment is signed by Carl L. Gordon with a signature date of 05/15/2026, as stated in the filing. The header also references the date 03/31/2026 for the amendment document.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

RAPT Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

75382E109

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 75382E109

1

Names of Reporting Persons

ORBIMED ADVISORS LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: RAPT Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 561 Eccles Avenue South San Francisco, California 94080
Item 2.
(a)	Name of person filing: OrbiMed Advisors LLC
(b)	Address or principal business office or, if none, residence: 601 Lexington Avenue, 54th Floor New York, NY 10022
(c)	Citizenship: Delaware.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 75382E109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Reporting Person holds 0.0% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC exercises investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ORBIMED ADVISORS LLC

Signature:	/s/ Carl L. Gordon
Name/Title:	Carl L. Gordon/Member
Date:	05/15/2026